GLP1R and hydrops fetalis: The novel glucose-lowering agents, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been shown to lower atherosclerotic CVD and HF risks independently of baseline HbA1c[44]; this has led to newer treatment approach.